研究单位：[1]Pfizer[2],Korea, Republic of,01830[3],Korea, Repu[4]The Second People's hospital of Hefei,Hefei,Anhui,China,230011[5]Beijing Friendship Hospital, Capital Medical University,Beijing,Beijing,China,100050[6]The First Medical Center of Chinese PLA General Hospital,Beijing,Beijing,China,100853[7]Chinese PLA General Hospital,Haidian District,Beijing,China,100853[8]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,400016[9]Hainan General Hospital,Haikou,Hainan,China,570311[10]Renmin Hospital Of Wuhan University,Wuhan,Hebei,China,430060[11]The First Affiliated Hospital of Henan University of Science &Technology,Luoyang,Henan,China,471003[12]People's Hospital of Zhengzhou,Zhengzhou,Henan,China,450014[13]Wuhan Third Hospital,Wuhan,Hubei,China,430074[14]Changsha Central Hospital,Changsha,Hunan,China,410004[15]The Third Xiangya Hospital of Central South University,Changsha,Hunan,China,410013[16]The Second People's Hospital of Lianyungang,Lianyungang,Jiangsu,China,222002[17]The Second People's Hospital of Lianyungang,Lianyungang,Jiangsu,China,222006[18]The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,China,210011[19]The Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,215004[20]Affiliated Hospital of Jiangnan University,Wuxi City,,Jiangsu,China,214125[21]Wuxi People's Hospital,Wuxi,Jiangsu,China,214023[22]The Affiliated Hospital of Jiangsu University,Zhenjiang City,Jiangsu,China,212008[23]The First Hospital of Jilin University,Changchun,Jilin,China,130000[24]The First Hospital of Jilin University,Changchun,Jilin,China,130021[25]The People's Hospital of Liaoning Province,Shenyang,Liaoning,China,110016[26]The People's Hospital of Liaoning Province,Shenyang,Liaoning,China,110067[27]General Hospital of Ningxia Medical Hospital,Yinchuan,NING XIA Province,China,750003[28]The First People's Hospital of Yinchuan,Yinchuan,Ningxia Province,China,750001[29]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi,China,710061[30]Shaanxi Provincial People' Hospital,Xi'an,Shaanxi,China,710068[31]Xian Gaoxin Hospital,Xi'an,Shaanxi,China,710075[32]Xianyang Hospital of Yan'an University,Xianyang City,,Shaanxi,China,716099[33]Qilu Hospital of Shandong University,Jinan,Shandong,China,250012[34]Jinan Central Hospital,Jinan,Shandong,China,250013[35]Affiliated Hospital of Jining Medical University,Jining City,Shandong,China,272000[36]Liaocheng people's Hospital,Liaocheng,Shandong,China,252000[37]Qingdao Central Hospital,Qingdao,Shandong,China,266042[38]People's Hospital of Rizhao,Rizhao City,Shandong,China,276800[39]Huashan Hospital, Fudan University,Shanghai,Shanghai,China,200040[40]Huashan Hospital, Fudan University,Shanghai,Shanghai,China,200040[41]Heping Hospital Affiliated to Changzhi Medical College,Changzhi,Shanxi,China,046000[42]First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan Sheng,China,650032[43]Xuanwu Hospital Capital Medical University,Beijing,China,100053[44]Chongqing University Three Gorges Hospital,Chongqing,China,404000[45]Shanghai East Hospital,Shanghai,China,200120[46]Tianjin Union Medical Center,Tianjin,China,300000[47]Seoul National University Bundang Hospital,Seongnam-si,Gyeonggi-do,Korea, Republic of,13620[48]Inje University - Ilsan Paik Hospital,Goyang-si,Kyǒnggi-do,Korea, Republic of,10380[49]Hallym University Dongtan Sacred Heart Hospital,Hwaseong-si,Kyǒnggi-do,Korea, Republic of,18450[50]Seoul National University Bundang Hospital,Seongnam,Kyǒnggi-do,Korea, Republic of,13620[51]Uijeongbu St. Mary's Hospital,Uijeongbu-si,Kyǒnggi-do,Korea, Republic of,11765[52]Dong-A University Hospital,Busan,Pusan-kwangyǒkshi,Korea, Republic of,49201
研究目的：
The purpose of this study is to learn how safe and effective zavegepant is compared to placebo in the acute treatment of migraine in Asian adults. Migraine is a very painful headache with other associated symptoms such as nausea, photophobia and phonophobia. A placebo is a harmless treatment that has no medical effect. This study is seeking for participants who: - have at least 1 year of migraine history before entering the study. - have 2 to 8 migraine headache attacks of moderate or severe intensity in each of the 3 months before entering the study. - have less than 15 days with headaches in each of the 3 months before entering the study. The headaches could be either due to migraine or not. The participants in this study will receive zavegepant or placebo through intranasal route. Intranasal means medicine which is given through nose. Zavegepant or placebo will be taken if the participants have a migraine headache of moderate or severe intensity. The study will compare the experiences of people receiving zavegepant to those of the people receiving placebo. This will help see if zavegepant is safe and effective in Asian adults. Participants will be in this study for up to about 16 weeks. Participants will have 3 study visits at the study clinic and 1 through telephone contact.
